Participants fulfilling all the following inclusion criteria are eligible for the study: |
1. Written informed consent |
2. Adults (≥18 years) |
3. Patients with a ureteral stent in situ |
4. Patients scheduled for endourological ureteral manipulations (e.g. endourological stone surgery, ureteral stent exchange) |
5. Asymptomatic bacteriuria with strains of E. coli and/or K. pneumoniae sensitive to ceftriaxone and amikacin. |
The presence of any one of the following exclusion criteria will lead to exclusion of the participant: |
1. Allergy to one of the study drugs or excipients (Beta-lactams, aminoglycosides or mannitol) |
2. Pregnant and lactating women |
3. Glomerular filtration rate (CKD-EPI eGFR) < 50ml/min / 1,73m2 |
4. Middle to severe hearing impairment |
5. Myasthenia gravis or other forms of myoneural disorders |
6. Congestive heart failure, pulmonary oedema |
7. Intracranial haemorrhage, compromised blood-brain barrier |
8. Antibiotic treatment within 14 days prior to randomization |
9. Mixed cultures of E. coli and/or K. pneumonia with other bacteria |
10. Previous (within 3 months prior to randomization) or concomitant participation in another interventional clinical trial |
11. Inability to understand and follow the protocol |
12. Inability to give informed consent |